Anebulo Pharmaceuticals, Inc. (ANEB) Earnings History
Net Loss6 years of earnings data (2020–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Anebulo Pharmaceuticals, Inc. (ANEB) Earnings Overview
As of June 30, 2026, Anebulo Pharmaceuticals, Inc. (ANEB) reported trailing twelve-month net income of -$8M, reflecting +21.9% year-over-year growth. The company earned $-0.19 per diluted share over the past four quarters.
Looking at the long-term picture, ANEB's historical earnings data spans multiple years. The company achieved its highest annual net income of -$174,637 in fiscal 2020.
Anebulo Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ATAI (-$663M net income, -16142.0% margin), CMPS (-$179M net income), MNMD (-$238M net income), ANEB has comparable earnings metrics. Compare ANEB vs ATAI →
ANEB Earnings vs Peers
Earnings metrics vs comparable public companies
ANEB Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$8M | -3.4% | -$9M | $-0.25 | - | - |
| 2024 | -$8M | +30.1% | -$8M | $-0.32 | - | - |
| 2023 | -$12M | -71.9% | -$12M | $-0.47 | - | - |
| 2022 | -$7M | +77.4% | -$7M | $-0.29 | - | - |
| 2021 | -$30M | -17223.4% | -$4M | $-1.30 | - | - |
| 2020 | $-174,637 | - | $-173,351 | $-0.01 | - | - |
Download Data
Export ANEB earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
6+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ANEB — Frequently Asked Questions
Quick answers to the most common questions about buying ANEB stock.
What is ANEB earnings per share (EPS)?
ANEB trailing twelve-month (TTM) diluted EPS is $-0.19, reflecting +21.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2020 to 2025 is available in the table on this page.
What is Anebulo Pharmaceuticals, Inc.'s net income?
Anebulo Pharmaceuticals, Inc. (ANEB) trailing twelve-month net income is $-8M as of 2025. Earnings grew +21.9% year-over-year.
Is ANEB profitable?
ANEB is not currently profitable on a TTM basis, reporting a net loss of $-8M. Net margin is N/A. Investors should monitor for a return to profitability.
What is ANEB's earnings growth rate?
ANEB compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2020 to 2025.
What are ANEB's profit margins?
Anebulo Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -109.7%.
Is ANEB growing earnings?
Yes, ANEB earnings are accelerating — EPS growth of +21.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-8M. Earnings momentum is strengthening.
What was ANEB's best earnings year?
Anebulo Pharmaceuticals, Inc.'s highest annual net income on record is $-174637.00, achieved in fiscal year 2020. Earnings history on this page spans 2020 to 2025 and includes all annual and quarterly figures.
What were ANEB's earnings last quarter?
ANEB's most recent reported quarter was Q2 2026. Net income was $-2M with diluted EPS of $-0.05. For a full breakdown of all quarters, see the quarterly earnings table on this page.